Literature DB >> 24593015

Depth and lateral spread of microscopic residual rectal cancer after neoadjuvant chemoradiation: implications for treatment decisions.

F M Smith1, H Wiland, A Mace, R K Pai, M F Kalady.   

Abstract

AIM: The aim of this study was to determine the distribution of residual tumour within the bowel wall in relation to residual mucosal abnormalities (RMAs) and surrounding normal mucosa in patients with rectal cancer who underwent neoadjuvant chemoradiation followed by curative surgery.
METHOD: Archived pathological slides from a cohort of 60 patients with residual tumour were retrieved. The incidence, distance and depth of tumour spread (ypT) under RMAs and adjacent normal mucosa were reviewed and recorded.
RESULTS: Histological sections containing both RMA and adjacent normal mucosa were available for 45 of 60 patients with ypT1 (n = 6), ypT2 (n = 18) and ypT3 (n = 21) disease. The maximal depth of invasion, as measured by ypT stage, was found underneath the RMA in 44 of 45 (98%) patients. Microscopic tumour spread lateral to the RMA and under adjacent normal mucosa was found in 32 of 45 (71%) patients. The median and maximum distances of lateral spread for ypT1 tumours were 0 and 4 mm; for ypT2 were 2.5 and 9 mm; and for ypT3 were 4 and 9 mm respectively.
CONCLUSION: Lateral tumour spread under normal mucosa adjacent to RMAs is a common finding and extended up to 9 mm in this study. The epicentre for maximum depth of invasion was directly underneath the RMAs in nearly all cases. These data have clinical and technical implications if local excision is to be considered. Colorectal Disease
© 2014 The Association of Coloproctology of Great Britain and Ireland.

Entities:  

Keywords:  Rectal cancer; lateral spread; neoadjuvant; radiotherapy; restaging; tumour scatter

Mesh:

Year:  2014        PMID: 24593015     DOI: 10.1111/codi.12608

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  9 in total

Review 1.  Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy.

Authors:  Reetesh K Pai; Rish K Pai
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

Review 2.  Non-operative management of rectal cancer: understanding tumor biology.

Authors:  Iris H Wei; Julio Garcia-Aguilar
Journal:  Minerva Chir       Date:  2018-05-24       Impact factor: 1.000

Review 3.  Organ-Preserving Strategies for the Management of Near-Complete Responses in Rectal Cancer after Neoadjuvant Chemoradiation.

Authors:  Patricio B Lynn; Paul Strombom; Julio Garcia-Aguilar
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

4.  Assessment of a novel, full-thickness incisional biopsy model to restage rectal tumours after neoadjuvant chemoradiotherapy: results of an ex vivo pilot study.

Authors:  F M Smith; H Wiland; A Mace; R K Pai; M F Kalady
Journal:  Tech Coloproctol       Date:  2015-02-17       Impact factor: 3.781

5.  MRI Assessment of Complete Response to Preoperative Chemoradiation Therapy for Rectal Cancer: 2020 Guide for Practice from the Korean Society of Abdominal Radiology.

Authors:  Seong Ho Park; Seung Hyun Cho; Sang Hyun Choi; Jong Keon Jang; Min Ju Kim; Seung Ho Kim; Joon Seok Lim; Sung Kyoung Moon; Ji Hoon Park; Nieun Seo
Journal:  Korean J Radiol       Date:  2020-07       Impact factor: 3.500

6.  Impact of the distal resection margin on local recurrence after neoadjuvant chemoradiation and rectal excision for locally advanced rectal cancer.

Authors:  Seung Ho Song; Jun Seok Park; Gyu-Seog Choi; An Na Seo; Soo Yeun Park; Hye Jin Kim; Sung-Min Lee; Ghilsuk Yoon
Journal:  Sci Rep       Date:  2021-11-25       Impact factor: 4.379

7.  Association of levels of metabolites with the safe margin of rectal cancer surgery: a metabolomics study.

Authors:  Shaopeng Zhang; Guoqiang Pan; Zhifeng Liu; Yuan Kong; Daguang Wang
Journal:  BMC Cancer       Date:  2022-10-05       Impact factor: 4.638

8.  The value of forceps biopsy and core needle biopsy in prediction of pathologic complete remission in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.

Authors:  Jing-Hua Tang; Xin An; Xi Lin; Yuan-Hong Gao; Guo-Chen Liu; Ling-Heng Kong; Zhi-Zhong Pan; Pei-Rong Ding
Journal:  Oncotarget       Date:  2015-10-20

9.  Should Local Excision After Neoadjuvant Therapy Be Included in the National Guidelines for the Treatment of Locally Advanced Rectal Cancer?

Authors:  Amr Aref; Amer M Alame; Ernesto R Drelichman; Abdelkader Hawasli
Journal:  Dis Colon Rectum       Date:  2022-04-01       Impact factor: 4.412

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.